Significant difference in drug susceptibility distribution between Mycobacterium avium and Mycobacterium intracellulare.

about

Non-tuberculous mycobacterial infection in hospitalized children: a case series.Assessing primary and secondary resistance to clarithromycin and amikacin in infections due to Mycobacterium avium complex.

P2860

Q38374388-7593C7BF-CFD5-4F43-8DF8-71ACEDA3F461 Q43223526-EC712DC6-4ACE-4AE5-A666-1B2D50998930

P2860

Significant difference in drug susceptibility distribution between Mycobacterium avium and Mycobacterium intracellulare.

Item

http://www.wikidata.org/entity/Q43126100

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

Significant difference in drug ...... Mycobacterium intracellulare.

@en

Significant difference in drug ...... Mycobacterium intracellulare.

@nl

type

Item

label

Significant difference in drug ...... Mycobacterium intracellulare.

@en

Significant difference in drug ...... Mycobacterium intracellulare.

@nl

prefLabel

Significant difference in drug ...... Mycobacterium intracellulare.

@en

Significant difference in drug ...... Mycobacterium intracellulare.

@nl

P1476

Significant difference in drug ...... Mycobacterium intracellulare.

@en

P2093

Aurélie Renvoisé

http://www.w3.org/2001/XMLSchema#string

Christine Bernard

http://www.w3.org/2001/XMLSchema#string

Eve Galati

http://www.w3.org/2001/XMLSchema#string

Vincent Jarlier

http://www.w3.org/2001/XMLSchema#string

P2860

Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.

An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.

Identification and partial characterization of Mycobacterium avium and Mycobacterium intracellulare by using DNA probes.

In vitro activity of amikacin against isolates of Mycobacterium avium complex with proposed MIC breakpoints and finding of a 16S rRNA gene mutation in treated isolates.

Current treatment of nontuberculous mycobacteriosis: an update.

Drug susceptibility distributions in slowly growing non-tuberculous mycobacteria using MGIT 960 TB eXiST.

Commercial DNA probes for mycobacteria incorrectly identify a number of less frequently encountered species.

Evaluation of the new GenoType Mycobacterium assay for identification of mycobacterial species.

Diagnosis of Nontuberculous Mycobacterial Infections

P304

4439-4440

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JCM.02127-14

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Nicolas Veziris

Jerome Robert

P577

2014-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

266572420

http://www.w3.org/2001/XMLSchema#string

P698

25274991

http://www.w3.org/2001/XMLSchema#string

P932

4313332

http://www.w3.org/2001/XMLSchema#string

Significant difference in drug susceptibility distribution between Mycobacterium avium and Mycobacterium intracellulare.

about

P2860

P2860

Significant difference in drug susceptibility distribution between Mycobacterium avium and Mycobacterium intracellulare.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P932